` SNDX (Syndax Pharmaceuticals Inc) vs S&P 500 Comparison - Alpha Spread

SNDX
vs
S&P 500

Over the past 12 months, SNDX has underperformed S&P 500, delivering a return of -60% compared to the S&P 500's +13% growth.

Stocks Performance
SNDX vs S&P 500

Loading
SNDX
S&P 500
Add Stock

Performance Gap
SNDX vs S&P 500

Loading
SNDX
S&P 500
Difference
www.alphaspread.com

Performance By Year
SNDX vs S&P 500

Loading
SNDX
S&P 500
Add Stock

Competitors Performance
Syndax Pharmaceuticals Inc vs Peers

S&P 500
SNDX
ABBV
AMGN
GILD
VRTX
Add Stock

Syndax Pharmaceuticals Inc
Glance View

Market Cap
814m USD
Industry
Biotechnology

Syndax Pharmaceuticals Inc. is carving out a distinctive niche in the biotechnology industry with a focus on developing therapies that modulate critical pathways involved in cancer and severe non-cancer indications. Founded in 2005, Syndax has its sights set on innovative epigenetic and immune-oncology treatments, harnessing the power of scientific breakthroughs to target hard-to-treat conditions. The company's primary approach revolves around inhibiting specific enzymes that alter the expression of genes, thereby reprogramming cancer cells to succumb to therapeutic intervention or effectively arming the immune system to target tumors. This strategic focus is not merely theoretical; it is grounded in a robust pipeline of clinical-stage drug candidates, which they steadily advance through focused research and strategic collaborations. Syndax generates revenue by developing these pioneering treatments and moving them through the rigorous stages of clinical trials towards regulatory approval. The ultimate goal is to bring their breakthrough medications to market, where they can provide significant medical benefits and address unmet needs in the oncology space. Their business model also includes collaborations and partnerships with larger pharmaceutical companies, which often entail milestone payments and royalties. By leveraging these strategic alliances, Syndax not only monetizes its innovations but also gains access to complementary expertise, enhancing its capabilities in developing and commercializing its investigational therapies. Through this two-pronged focus on groundbreaking research and strategic partnerships, Syndax has positioned itself as a dynamic player poised to make significant contributions to the field of medicine.

SNDX Intrinsic Value
19.36 USD
Undervaluation 51%
Intrinsic Value
Price
Back to Top